Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced results from a Phase 4 study of its pain medication JOURNAVX that showed 90.9 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE